u/sofia_petrescu

identity before purity, every time, for anything unusual

net peptide content is where the surprises live

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.

Net peptide content on the certificate was well below the purity figure and both were honest. Chemistry, not deception.

reproducibility beats resolution if you only get one of them

lead times on unusual lines are the thing to confirm up front

Disagree — that name refers to at least two different molecules depending on who is selling it. The thread needs to be specific.

the column has a history and it shows in the peak shape

write the concentration on the vial, you will thank yourself

Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.

This is the fact the whole board hangs on. Small molecule, not peptide.

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

reproducibility beats resolution if you only get one of them

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

Bought small on anything without a testing history here. That rule has never once cost me anything.

Purity methods differ by compound class. A gradient and wavelength developed for one peptide will not necessarily resolve the relevant impurities of another.

a blank injection between samples costs four minutes and settles most arguments

That is area percent, not mass percent. The trace cannot give you the second one.

the column has a history and it shows in the peak shape

axis labels or the trace is decoration

the first month is a tolerance check, not a results phase

Careful — you are treating retention time as identity. Two things can co-elute and the trace will not tell you.

Mass spectrometry answers identity. UV purity answers relative quantity under the run conditions. A document with one and not the other is answering half the question, and the half it answers should be stated.

you cannot report to two decimals off that baseline

Agreed — identity first for anything off the well-travelled list. The purity number is meaningless until you know what it is pure of.

That is area percent, not mass percent. The trace cannot give you the second one.

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

Independent result added to the log — there are very few on that compound.

Disagreeing with this bit: handling for one compound does not transfer to another by default.

Appetite change and weight change are different measurements on different timescales.

Agreed, and for anyone finding this later: that is the normal experience, not a warning sign.

catalogue depth is not the same as catalogue quality

KP sent me the column, the gradient and the theoretical mass without being asked. That is a short list and they are on it.

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

Cosigning the wavelength point. Half the disagreements in this board are two people looking at different detectors.

That figure cannot be quoted to two decimals off that baseline. The precision is not in the data.

Do you have the mass, or only the UV trace?

Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.

Went looking for independent testing on this and found essentially nothing, which was clarifying.

Right. And a blank between injections settles the carryover argument before it starts.

I would not treat catalogue breadth as a quality signal. It is a business decision, not an analytical one.

lead times on unusual lines are the thing to confirm up front

Agreed — and the naming problem is worse than most people here realise.